Boosting Accruals for NCI-Funded Clinical Trials in GU Cancers at Yale Cancer Center

提高耶鲁大学癌症中心 NCI 资助的 GU 癌症临床试验的收益

• 批准号: 10328295
• 负责人: Nita Ahuja
• 金额: $ 6万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10328295
• 关键词: Address; Adoptive Cell Transfers; Area; Award; Basic Science; Biological Markers; Biostatistics Shared Resource; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Science; Catchment Area; Charge; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communication; Communities; Community Outreach; Comprehensive Cancer Center; Development; Direct Costs; Discipline; Dreams; Early Diagnosis; Education; Evaluation; Extramural Activities; Faculty; Fostering; Funding; Future; Genomics; Goals; Grant; Heart; Immunooncology; Incubators; Individual; Infrastructure; Institutes; Institutional Policy; Intervention; Investments; Laboratories; Leadership; Malignant Neoplasms; Medicine; Mission; Patient Selection; Patient-Centered Care; Patients; Phase; Physicians; Population; Population Research; Prevention; Procedures; Process; Recording of previous events; Research; Research Personnel; Resource Sharing; Resources; Science; Scientist; Strategic Planning; Talents; Teacher Professional Development; Technology; Time; Training; Training and Education; Translational Research; Translations; Yale Cancer Center; anticancer research; arm; bench to bedside; cancer care; cancer diagnosis; cancer prevention; cancer therapy; clinical investigation; community engagement; cost effective; design; diversity and equity; experience; health equity; health inequalities; improved; innovation; interdisciplinary collaboration; member; next generation; novel; novel therapeutic intervention; prevent; programs; recruit; research and development; synergism; therapy resistant; translational scientist; treatment trial

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, and clinical scientists representing all biomedical disciplines. YCC arms these investigators with a suite of enabling cores and powerful collaborative opportunities and resources. Through intra- and inter-programmatic collaboration, the overarching goals of YCC are to understand and prevent cancer, detect cancer early, and manage cancer treatment more accurately and effectively. The seven Research Programs are the heart of YCC, and each program is led by a basic scientist in partnership with a clinical/translational scientist to foster transdisciplinary research and the advancement of Yale science from the bench to the clinic. In addition, YCC supports and manages Shared Resources that provide unique expertise and enabling technologies that enrich the scope and expedite progress of each Research Program. YCC infrastructure further enables ground-breaking clinical trials that capitalize on Yale science and incorporate novel designs and biomarker assessments to optimize patient selection, define treatment resistance, and inform new therapeutic approaches. Overall cancer funding (direct costs) has increased 51% from $58.2M in 2012 to $88M in 2017, including an increase from $17.8M to $23.5M in NCI funding (direct costs). YCC holds two NCI SPORE grants, a UM1, U10, multiple P01s, numerous multi- investigator R01 grants, and leadership in two SU2C Dream Team awards. Additionally, during the current funding cycle, YCC leveraged $5.9M, reflecting CCSG Developmental Funds and institutional support, to advance new research and collaborations, resulting in $55.6M in new extramural funding - a 9-fold return on investment. During the same period, accrual to interventional treatment trials increased 82%, from 471 to 859, and accruals to early-phase treatment trials (pilot, I, I-II) increased three-fold, now representing 44% of total treatment accruals. No less important, YCC has expanded and invested in initiatives and research that seeks to impact cancer inequities and the needs of our catchment area at an individual, institutional, and policy level. Over the next five years, YCC will continue to develop initiatives and resources to foster innovation, collaboration, excellence and synergy to maximize the impact of Yale’s talent and expertise on the understanding, prevention and treatment of cancer.!

全面的 项目摘要/摘要！ 耶鲁大学癌症中心 (YCC) 作为 NCI 指定的综合癌症中心已进入第 43 个年头 建立了高影响力癌症研究的强大传统以及深厚的沟通和文化文化 代表所有生物医学领域的 286 名基础科学家、转化科学家、人口科学家和临床科学家联合起来的合作 学科。 YCC 为这些调查人员提供了一套支持核心和强大的协作能力 机会和资源。通过计划内和计划间的合作，总体目标 YCC旨在了解和预防癌症，及早发现癌症，并更多地管理癌症治疗 准确有效。七个研究项目是 YCC 的核心，每个项目均由一位 基础科学家与临床/转化科学家合作，促进跨学科研究和 耶鲁科学从实验室到临床的进步。此外，YCC 支持和管理共享 提供独特专业知识和支持技术的资源，可丰富范围并加快速度 每个研究计划的进展。 YCC 基础设施进一步支持突破性的临床试验 利用耶鲁科学并结合新颖的设计和生物标志物评估来优化患者 选择、定义治疗耐药性并为新的治疗方法提供信息。总体癌症资助（直接 成本）从 2012 年的 5820 万美元增加到 2017 年的 8800 万美元，增加了 51%，其中从 1780 万美元增加到 2350 万美元 NCI 资助（直接成本）。 YCC 拥有两项 NCI SPORE 资助、一项 UM1、U10、多项 P01、众多多 研究员 R01 资助，并领导两项 SU2C 梦之队奖项。此外，当前期间 在融资周期中，YCC 杠杆化了 590 万美元，反映了 CCSG 发展基金和机构支持，以 推进新的研究和合作，带来 5560 万美元的新外部资金——回报率的 9 倍 投资。同期，介入治疗试验的应计增加了 82%，从 471 项增加到 859 项， 早期治疗试验（试点、I、I-II）的应计费用增加了三倍，目前占总数的 44% 治疗应计费用。同样重要的是，YCC 已扩大并投资于旨在寻求 在个人、机构和政策层面影响癌症不平等和我们学区的需求。 未来五年，YCC 将继续开发举措和资源来促进创新、 合作、卓越和协同作用，最大限度地发挥耶鲁人才和专业知识对世界的影响 了解、预防和治疗癌症！